Skip to main content
Ingredients/General/LH01 Myoviridae Bacteriophage

LH01 Myoviridae Bacteriophage.

A targeted bacteriophage that selectively kills harmful gut bacteria without touching the good ones. Selectively infects and destroys specific strains of harmful gut bacteria without harming good bacteria or human cells.

EarlyResearch strength

Reviewed March 2026

LMGeneral
LH01 Myoviridae BacteriophageIngredientMD
Category
General

Also filed under
Targeted pathogen eliminationMicrobiome preservationNo antibiotic resistance

What LH01 Myoviridae Bacteriophage is, and what it does.

Does it work
Fascinating science, but individual phage strain data is extremely limited for supplements.
How much to take
Dosed in PFU (plaque-forming units), not milligrams. Typically part of a multi-phage cocktail. Follow the product label.
Time to feel it
No onset has been measured for this phage on its own, and no dose figure is on record. What it does happens in the gut lumen, showing up in stool measures rather than in sensation.
The first dose
Usually nothing noticeable. Phages work at the microbial level, not the 'I feel something' level.
With regular use
Potential microbiome rebalancing over weeks to months. Long-term supplement data is sparse.
How well tolerated
Generally considered well tolerated. Phages are naturally present in your gut by the billions. They can't infect human cells.
How it feels
You won't feel the phages working. Any benefit shows up as improved digestion over time.
The overlooked benefit
Its numbers only rise where its target bacterium is present, so it is self-limiting. It cannot adsorb to Lactobacillus or Bifidobacterium, which is why it ships alongside them.

The proof, claim by claim.

These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.

  • Kills harmful bacteria selectively
  • Improves gut health
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.

Questions people ask about LH01 Myoviridae Bacteriophage.

What's a bacteriophage?
A virus that only attacks bacteria. Can't infect human cells at all. They're nature's original antibiotic, predating human medicine by billions of years.
Is this the same as phage therapy?
Similar concept, different application. Clinical phage therapy uses personalized phage cocktails for serious infections. Supplements use standardized strains for general gut health.
Can phages hurt my good bacteria?
Each phage only targets very specific bacterial strains. LH01 targets harmful bacteria, not your beneficial microbes. It's like a sniper, not a bomb.
Why haven't I heard of phage supplements before?
They're relatively new in the supplement world. Phage therapy has been used in Eastern Europe since the 1920s, but it's just now entering mainstream Western supplements.
Do I need to take this with probiotics?
Not necessarily, but they can complement each other. Phages reduce bad bacteria, probiotics add good ones. Different mechanisms, potentially synergistic.
How is this different from antibiotics?
Antibiotics kill bacteria broadly (good and bad). Phages are extremely specific, only targeting certain strains. No collateral damage to your microbiome.
Pairs well with23 on file

Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.

LH01 Myoviridae Bacteriophage + Probioticsphage clears a competing coliform niche

LH01 is a lytic phage with a narrow host range against specific Escherichia coli strains, so it lyses those cells and frees nutrients and adhesion sites in the same intestinal niche. Co dosed probiotic strains, which the phage cannot infect, are the ones positioned to use that space.

LH01 Myoviridae Bacteriophage + Lactobacillus plantarumselective lysis of a competitor, not the probiotic

Phage host range is strain specific and this coliform phage does not infect lactobacilli, so it removes a competing population without touching the delivered strain. That is the basis for pairing coliform phages with Lactobacillus in a single formula.

LH01 is a coliphage with a narrow host range, so it lyses specific Escherichia coli strains and leaves gram-positive commensals such as bifidobacteria untouched. Removing a competing population frees luminal nutrients and adhesion sites. That is the mechanistic basis for pairing a phage preparation with a probiotic rather than a measured result for this combination.

Bacteriophages recognise their host through specific surface receptors, and a coliphage cannot adsorb to a Bifidobacterium cell. The probiotic therefore passes through unaffected while the phage acts on its own target. Formulators use that specificity to combine the two in one capsule.

Lactobacillus species are gram-positive and outside the host range of a coliphage, so co-administration does not put the probiotic at risk. The pairing is the usual commercial format for phage preparations. Whether the combination changes anything measurable beyond the probiotic alone is not established in the candidate literature.

Bacteriophages infect bacteria only, so a yeast preparation is entirely outside the phage host range. The two act on different parts of the gut community with no direct interaction. Read the pairing as compatible rather than synergistic.

Inulin feeds bifidobacteria and other saccharolytic commensals, while a phage reduces a specific competing population. Making space and feeding the residents are complementary moves on the same community. The reasoning is ecological and the combined effect has not been quantified.

Short-chain fructooligosaccharides are fermented in the proximal colon by bifidobacteria. A phage acting on a competing coliform in the same region complements that selective feeding. The pairing is standard in synbiotic-style formulas.

Galactooligosaccharides support bifidobacterial growth and also act as decoy receptors for some bacterial adhesins in the lumen. Combined with a host-specific phage, both work on which organisms dominate rather than on the host directly. This is mechanism, not a measured combination.

Resistant starch reaches the colon intact and feeds butyrate-producing communities. Phage-driven changes to community composition and substrate-driven changes act on the same ecosystem from different directions. Short-chain fatty acid output is a marker of fermentation, not an outcome by itself.

Partially hydrolysed guar gum is a well tolerated fermentable fibre that shifts the fermenting population. Pairing it with a phage preparation stacks two ways of changing which organisms dominate. Grounding is ecological and confidence stays low.

Butyrate supplied directly acts on colonocyte energy metabolism, while a phage acts on the composition of the community that would otherwise produce it. The two reach the same endpoint from opposite ends. No study in the candidate set measured the pair.

Glutamine is the preferred fuel of enterocytes and supports normal tight junction protein expression, which is a host-side effect. A phage acts on the luminal bacterial community, which is a microbial-side effect. Formulas combine them for that split, and the split is the whole rationale.

Bovine colostrum supplies immunoglobulins and oligosaccharides that bind bacterial adhesins in the lumen. A phage reduces specific host bacteria by lysis. Both act on bacterial populations without being absorbed, though nothing in the candidate literature measures them together.

Zinc carnosine adheres to the mucosal surface and is studied for support of normal mucosal integrity, a host-tissue effect. The phage acts in the lumen on bacteria. Combining a host-side and a microbe-side ingredient is formulation logic rather than a demonstrated interaction.

Slippery elm mucilage forms a viscous layer over the mucosal surface, which can slow diffusion of particles including phage through to the epithelial interface. Whether that matters for a lumen-acting phage is unknown. The row exists to flag the physical consideration, not to claim an effect.

Tailed phages lose infectivity at gastric pH, and most preparations are formulated to survive transit. Raising gastric pH transiently with bicarbonate reduces the acid load a phage particle meets. This is a survival-of-the-particle argument taken from phage stability work, not a measured gain in effect.

Betaine hydrochloride is taken deliberately to lower gastric pH, which is the condition under which tailed phage particles are most rapidly inactivated. Taking the two in the same dose is working against the phage. Separating them by a couple of hours is the straightforward answer.

A phage capsid and tail are made of protein, and supplemental proteases including pepsin and pancreatin degrade protein in the lumen. High-strength protease taken at the same time can reduce the number of intact particles reaching the colon. The concern is mechanistic and depends on formulation and enteric protection.

Activated charcoal has an enormous adsorptive surface and binds particles and macromolecules non-selectively in the gut lumen. Phage particles are large protein assemblies and are the sort of material charcoal adsorbs. Taking the two together is likely to reduce the phage dose that stays free, so space them apart.

Bentonite is a charged aluminosilicate that binds proteins and viruses to its layered surface, a property used in water treatment. A phage preparation taken alongside it can be adsorbed and carried out. This is a physical binding issue and is straightforward to avoid by separating doses.

Broad-spectrum antimicrobial botanicals such as oregano oil reduce bacterial numbers indiscriminately, including the host bacteria a phage needs in order to replicate. Fewer hosts means less phage amplification in the gut. The interaction is inferred from phage biology rather than measured for this pair.

Lactoferrin sequesters iron and binds bacterial surface lipopolysaccharide, limiting growth of iron-dependent gram-negative organisms. A coliphage lyses a subset of the same group. Two different pressures on the same population, with no study in the candidate set measuring them together.

Who should be cautious

Talk to a doctor before taking LH01 Myoviridae Bacteriophage if any of these apply to you: Very limited clinical data for oral supplementation, Narrow host range. These are flags to check first, not effects LH01 Myoviridae Bacteriophage is known to cause.

Not medical advice. Show the label to your pharmacist.

What LH01 Myoviridae Bacteriophage actually does.

Established

The phage docks onto a matching bacterium, punches through the wall and injects its genetic material.

Established

It copies itself inside the bacterium and then bursts the cell open to get out.

Established

It only attaches to the bacteria whose surface it matches, so probiotic species are not affected.

Established

Phages stay in the gut and only multiply where their target bacteria are.

Grown by microbes, 7 steps on record

Where LH01 Myoviridae Bacteriophage comes from.

It starts as a naturally occurring virus of bacteria, found in the environment and picked out as a single pure strain. It is grown on a harmless lab strain of its target bacterium, filtered and concentrated, counted, then freeze dried into a powder.

Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.

Starts as
Environmental isolation

Candidate phages are recovered from environments rich in their bacterial hosts, typically wastewater or surface water, by enrichment against a chosen host strain.

Converted by
Plaque purification and characterisation

Single plaques are picked and repropagated to a clonal stock, then characterised by morphology, genome sequencing and host range. Sequencing is used to confirm a strictly lytic lifecycle and the absence of toxin or resistance genes.

Converted by
Propagation on a defined host

The phage is amplified in a fermenter on a well characterised, non-pathogenic host strain until the culture lyses.

Extracted by
Clarification

Bacterial debris is removed by centrifugation and depth filtration, leaving a phage-containing filtrate.

Purified by
Concentration and endotoxin reduction

Tangential flow filtration, and sometimes chromatography or density gradient steps, concentrate the particles while reducing residual host protein and endotoxin, which is a specified limit for gram-negative host systems.

Standardised to
Titre assay

Potency is set by plaque assay against the propagation host and declared as plaque-forming units per gram or per serving, with sterility and endotoxin testing alongside.

Ends up as
Lyophilisation or buffered liquid

The concentrate is freeze dried with a cryoprotectant into a stable powder, or held as a buffered liquid for liquid products.

Getting LH01 Myoviridae Bacteriophage from food.

The whole-food sources on file. A supplement closes the gap, it does not replace dinner.

Raw water sources

A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.

The forms it comes in.

Freeze-dried phage powderThe purified phage suspension is freeze dried with a cryoprotectant such as trehalose or sucrose, giving a dry powder in which titre is stated as plaque-forming units per gram.Fits Two-piece capsules, tablets and dry blends held with probiotic strains.Trade-off Titre falls with heat and humidity over shelf life, so storage conditions and the overage built in at manufacture determine what is left at expiry.
Liquid phage suspension in bufferPhage held in a buffered saline or SM-type buffer, sometimes with glycerol, with titre expressed per millilitre.Fits Liquid products and drops.Trade-off Needs cold storage and pH control, and gives no protection from stomach acid on its own.
Phage powder in a delayed-release capsuleThe dried phage is filled into a capsule with a pH-dependent coating that stays closed at gastric pH and opens in the small intestine.Fits Products where survival past the stomach is the design priority.Trade-off Adds coating material and cost, and release depends on gastric emptying and on how acidic the stomach is at the time.Active and formulation aid
What the strongest studies found

The essence, in one line each.

  1. In a 4-week randomised, double-blind, placebo-controlled trial in 68 healthy adults, adding a bacteriophage blend containing LH01 to a Bifidobacterium animalis subsp. lactis probiotic showed a within-group improvement in a self-reported gut symptom score (p = 0.01) and a larger rise in Lactobacillus and short-chain fatty acid producing bacteria than the probiotic alone.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
  2. The authors review how bacteriophages shape gut microbial community structure, describing lytic predation of specific bacterial hosts and the resulting shifts in community composition.Narrative review. Mahmud MR et al., 2024 (Gut Microbes). PMID 39167701 ↗
  3. A review of bacteriophages used in food supplements obtained from natural sources, covering how they are isolated, their host specificity, and the state of the supporting evidence.Narrative review. Kiani AK et al., 2020 (Acta Bio-Medica: Atenei Parmensis). PMID 33170168 ↗

These are the studies our verdict leans on, chosen from the 7 we read for LH01 Myoviridae Bacteriophage. The full linked list is below.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.

On the shelf

What LH01 Myoviridae Bacteriophage comes in.

Products in our catalog that carry it, read the same way every product here is read.